natgillin/translations-raw huggingface dataset:
The population included 27.8% women, 58.4% patients ≥ 60 years (26% ≥ 70 years) and
Populacija bolesnika uključivala je 27,8% žena, 58,4%
Thrombotic thrombocytopenic purpura (TTP) (see section 4.4), aplastic anaemia, pancytopenia, agranulocytosis, severe thrombocytopenia, acquired haemophilia A, granulocytopenia, anaemia
Trombotična trombocitopenična purpura (TTP) (vidjeti dio 4.4), aplastična anemija, pancitopenija, agranulocitoza, teška trombocitopenija,
Thrombocytopenia, leucopenia, eosinophilia
Trombocitopenija, leukopenija, eozinofilija
If you take more Clopidogrel ratiopharm GmbH than you should
Ako uzmete više Klopidogrel ratiopharm GmbH nego što ste trebali:
If you are pregnant or suspect that you are pregnant, you should tell your doctor or your pharmacist before taking Clopidogrel ratiopharm GmbH.
Ako ste trudni ili sumnjate na trudnoću, obavijestite svog liječnika ili ljekarnika prije nego što uzmete
Clopidogrel ratiopharm GmbH 75 mg
Klopidogrel ratiopharm GmbH 75 mg
-Uncommon side effects (may affect up to 1 in 100 people):
-Manje česte nuspojave (mogu se javiti u manje od 1 na 100 osoba):
Patients were randomised to clopidogrel (300 mg loading dose followed by 75 mg/day, N = 6,259) or placebo (N = 6,303), both given in combination with ASA (75-325 mg once daily) and other standard therapies.
Bolesnici su randomizirani u skupine koje su primale klopidogrel (udarna doza od 300 mg, a nakon toga 75 mg/dan, N=6259) ili placebo (N=6303), oboje u kombinaciji s ASK (75 do 325 mg jedanput dnevno) i drugom standardnom terapijom.
The number of patients experiencing the primary endpoint [cardiovascular (CV) death, myocardial infarction (MI), or stroke] was 582 (9.3%) in the clopidogrel-treated group and 719 (11.4%) in the placebo-treated group, a 20% relative risk reduction (95% CI of 10%-28%; p=0.00009) for the clopidogrel-treated group (17% relative risk reduction when patients were treated conservatively, 29% when they underwent percutaneous transluminal coronary angioplasty (PTCA) with or without stent and 10% when they underwent coronary artery bypass graft (CABG).
Broj bolesnika koji su doživjeli primarni ishod [kardiovaskularna smrt, infarkt miokarda ili moždani udar] bio je 582 (9,3%) u skupini koja je primala klopidogrel i 719 (11,4%) u skupini koja je primala placebo, uz 20%-tno smanjenje relativnog rizika (95% CI od 10% do 28%; p=0,00009) u skupini koja se liječila klopidogrelom (17% smanjenje relativnoga rizika u bolesnika koji su liječeni konzervativno,
Gastrointestinal haemorrhage, diarrhoea, abdominal pain, dyspepsia
Gastrointestinalno krvarenje, proljev, bol u trbuhu, dispepsija
Package leaflet: Information for the user Clopidogrel ratiopharm GmbH 75 mg film-coated tablets clopidogrel
Uputa o lijeku: Informacije za korisnika Klopidogrel ratiopharm GmbH 75 mg filmom obložene tablete klopidogrel
Cellulose, microcrystalline (E460) Crospovidone type A Castor oil, hydrogenated
celuloza, mikrokristalična (E460)
Therefore, concomitant use should be undertaken with caution (see section 4.4).
Zbog toga je kod istodobne primjene potreban oprez (vidjeti dio 4.4).
Consequently, NSAIDs including Cox-2 inhibitors and clopidogrel should be co-administered with caution (see section 4.4).
Stoga je potreban oprez pri istodobnoj primjeni NSAIL, uključujući Cox-2 inhibitore i klopidogrela (vidjeti dio 4.4).
Serious haemorrhage, haemorrhage of operative wound, vasculitis, hypotension
Ozbiljno krvarenje, krvarenje kirurške rane, vaskulitis, hipotenzija
• Renal impairment Therapeutic experience is limited in patients with renal impairment (see section 4.4).
Terapijsko iskustvo u bolesnika s narušenom funkcijom bubrega je ograničeno (vidjeti dio 4.4).
The decrease was associated with a 39% (loading dose) and 21% (maintenance dose) reduction of inhibition of platelet aggregation Esomeprazole is expected to give a similar interaction with clopidogrel.
Smanjenje je bilo povezano s oslabljenom inhibicijom agregacije trombocita od 39% (udarna doza) i 21% (doza održavanja).
A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
PRILOG II A. PROIZVOĐAČI ODGOVORNI ZA PUŠTANJE SERIJE LIJEKA U PROMET
STATEMENT OF ACTIVE SUBSTANCE(S)
Pomoćna(e) tvar(i)
Haematoma
Hematomi
While you are taking Clopidogrel ratiopharm GmbH:
Dok uzimate Klopidogrel ratiopharm GmbH:
Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction): clopidogrel treatment should be initiated with a single 300 mg loading dose and then continued at 75 mg once a day (with acetylsalicylic acid (ASA) 75 mg-325 mg daily).
infarkt miokarda): liječenje klopidogrelom treba započeti s jednokratnom udarnom dozom od 300 mg, a zatim nastaviti sa 75 mg jedanput dnevno (uz acetilsalicilatnu kiselinu (ASK) 75 mg do 325 mg dnevno).
Other medicines and Clopidogrel ratiopharm GmbH
Drugi lijekovi i Klopidogrel ratiopharm GmbH
Clopidogrel ratiopharm GmbH is taken by adults to prevent blood clots (thrombi) forming in hardened blood vessels (arteries), a process known as atherothrombosis, which can lead to atherothrombotic events (such as stroke, heart attack, or death).
(tromba) u otvrdnutim krvnim žilama (arterijama), a taj poremećaj zove se aterotromboza i može dovesti do aterotrombotičkih događaja (kao što su moždani udar, srčani udar ili smrt).
If you forget to take a dose of Clopidogrel ratiopharm GmbH, but remember within 12 hours of your usual time, take your tablet straight away and then take your next tablet at the usual time.
Ako zaboravite uzeti jednu dozu Klopidogrel ratiopharm GmbH, ali se toga sjetite u roku od 12 sati,
In particular, in a post-hoc analysis in 2,172 patients (17% of the total CURE population) who underwent stent placement (Stent-CURE), the data showed that clopidogrel compared to placebo, demonstrated a significant RRR of 26.2% favouring clopidogrel for the co-primary endpoint (CV death, MI, stroke) and also a significant RRR of 23.9% for the second co-primary endpoint (CV death, MI, stroke or refractory ischaemia).
U tzv. post-hoc analizi 2172 bolesnika (17% ukupne CURE populacije) koji su se podvrgli ugradnji stenta (Stent-CURE), podaci su pokazali da je klopidogrel u usporedbi s placebom pokazao značajno smanjenje relativnog rizika od 26,2% za koprimarni ishod
If you experience prolonged bleeding when taking Clopidogrel ratiopharm GmbH.
Ako pri uzimanju Klopidogrela ratiopharm GmbH imate produljeno krvarenje
Overall, clopidogrel 75 mg/day was comparable to ASA 325 mg/day in CAPRIE regardless of age, gender and race.
Podaci za klopidogrel u dozi od 75 mg/dan bili su slični podacima za ASK u dozi od 325 mg/dan u CAPRIE
What you need to know before you take Clopidogrel ratiopharm GmbH Do not take Clopidogrel ratiopharm GmbH
Što morate znati prije nego počnete uzimati Klopidogrel ratiopharm GmbH
Vascular disorders
Bulozni dermatitis
SSRIs: since SSRIs affect platelet activation and increase the risk of bleeding, the concomitant administration of SSRIs with clopidogrel should be undertaken with caution.
Selektivni inhibitori ponovne pohrane serotonina (SSRI): budući da lijekovi iz skupine SSRI utječu na aktivaciju trombocita i povećavaju rizik od krvarenja, potreban je oprez prilikom istodobne primjene
Clopidogrel ratiopharm GmbH 75 mg film-coated tablets
Klopidogrel ratiopharm GmbH 75 mg filmom obložene tablete
Glomerulonephritis, blood creatinine increased
Glomerulonefritis,
Clopidogrel ratiopharm GmbH 75 mg film-coated tablets clopidogrel
Klopidogrel ratiopharm GmbH 75 mg filmom obložene tablete klopidogrel
You should specifically tell your doctor if you take - medicines that may increase your risk of bleeding such as: o oral anticoagulants, medicines used to reduce blood clotting, o a non-steroidal anti-inflammatory medicine, usually used to treat painful and/or inflammatory conditions of muscle or joints o heparin or any other injectable medicine used to reduce blood clotting o ticlopidine, other antiplatelet agent, o a selective serotonin reuptake inhibitor (including but not restricted to fluoxetine or fluvoxamine), medicines usually used to treat depression, - omeprazole or esomeprazole, medicines to treat upset stomach - fluconazole or voriconazole medicines to treat fungal infections
o selektivne inhibitore ponovne pohrane serotonina (uključujući, ali ne ograničeno na fluoksetin i fluvoksamin), lijekove koji se obično koriste za liječenje depresije, - omeprazol ili esomeprazol, lijekove za smanjenje želučanih tegoba, - flukonazol ili vorikonazol, lijekove koji se primjenjuju za liječenje gljivičnih infekcija, - efavirenz, lijek koji se primjenjuje za liječenje HIV (virus humane imunodeficijencije) infekcija, - antiretrovirusne lijekove (lijekovi za liječenje infekcije HIV-om), - karbamazepin, lijek koji se primjenjuje za liječenje nekih oblika epilepsije, - moklobemid, lijek za liječenje depresije, - repaglinid, lijek za liječenje dijabetesa,
If you think any of these apply to you, or if you are in any doubt at all, consult your doctor before taking Clopidogrel ratiopharm GmbH.
Ako se bilo što od navedenog odnosi na Vas, ili niste sigurni, obratite se svom liječniku prije uzimanja
(alone or in combination with ASA), and that they should report any unusual bleeding (site or duration) to their physician.
Bolesnicima koji uzimaju klopidogrel (kao monoterapiju ili u kombinaciji s ASK) potrebno je objasniti da će krvarenje možda trajati dulje nego obično i da moraju obavijestiti liječnika o bilo kakvom neočekivanom krvarenju (s obzirom na mjesto i trajanje krvarenja).
Patients received clopidogrel (300 mg loading dose, followed by 75 mg/day, n=1752) or placebo (n=1,739), both in combination with ASA (150 to 325 mg as a loading dose, followed by 75 to 162 mg/day), a fibrinolytic agent and, when appropriate, heparin.
(najprije udarnu dozu od 300 mg, a nakon toga dozu od 75 mg na dan, n=1752) ili placebo (n=1739), oboje u kombinaciji s ASK (150 do 325 mg kao udarna doza nakon čega je slijedila doza od 75 do
If you forget to take Clopidogrel ratiopharm GmbH
Ako ste zaboravili uzeti Klopidogrel ratiopharm GmbH:
If you have experienced severe chest pain (unstable angina or heart attack), you may be prescribed Clopidogrel ratiopharm GmbH in combination with acetylsalicylic acid, a substance present in many medicines used to relieve pain and lower fever.
Klopidogrel ratiopharm GmbH u kombinaciji s acetilsalicilatnom kiselinom, tvari prisutnom u mnogim lijekovima za ublažavanje boli i snižavanje temperature.
Haematuria
Vrtoglavica
The clinically relevant adverse reactions observed in the CAPRIE, CURE, CLARITY and COMMIT studies are discussed below.
Klinički značajne nuspojave opažene u studijama CAPRIE,
How to take Clopidogrel ratiopharm GmbH
Kako uzimati Klopidogrel ratiopharm GmbH
If prompt correction of prolonged bleeding time is required, platelet transfusion may reverse the effects of clopidogrel.
Ako je potrebno hitno korigirati produljeno vrijeme krvarenja,
A crossover study in 40 healthy subjects, 10 each in the four CYP2C19 metaboliser groups (ultrarapid, extensive, intermediate and poor), evaluated pharmacokinetic and antiplatelet responses using 300 mg followed by 75 mg/day and 600 mg followed by 150 mg/day, each for a total of 5 days (steady state).
umjereni i slabi), procijenjen je farmakokinetički i antitrombocitni odgovor primjenom doze od 300 mg, nakon čega je slijedila doza od 75 mg/dan te doze od 600 mg, nakon čega je slijedila doza od 150 mg/dan, u trajanju od ukupno 5 dana (stanje dinamičke ravnoteže).
Musculoskeletal , connective tissue and bone disorders
Poremećaji mišićno-koštanog sustava i vezivnog tkiva
Tablet core:
Propuštena doza:
In the intention to treat analysis, 939 events were observed in the clopidogrel group and 1,020 events with ASA (relative risk reduction (RRR) 8.7%, [95% CI: 0.2 to 16.4]; p=0.045), which corresponds, for every 1,000 patients treated for 2 years, to 10 [CI: 0 to 20] additional patients being prevented from experiencing a new ischaemic event.
[95% CI: 0,2 do 16,4]; p=0,045) što odgovara broju od dodatnih 10 bolesnika kojima je spriječen novi ishemijski događaj na svakih 1000 bolesnika liječenih 2 godine [CI: 0 do 20]. Analiza ukupne smrtnosti sekundarnog ishoda studije nije pokazala značajnu razliku između klopidogrela (5,8%) i
If you become pregnant while taking Clopidogrel ratiopharm GmbH, consult your doctor immediately as it is recommended not to take clopidogrel while you are pregnant.
odmah se posavjetujte s liječnikom, jer nije preporučeno uzimati klopidogrel za vrijeme trudnoće.
Bleeding time prolonged, neutrophil count decreased, platelet count decreased * Information related to clopidogrel with frequency “not known”
Produljeno vrijeme krvarenja, smanjeni broj neutrofila, smanjeni broj trombocita
Gastric ulcer and duodenal ulcer, gastritis, vomiting, nausea, constipation, flatulence
Ulkus želuca i dvanaesnika, gastritis,
How to store Clopidogrel ratiopharm GmbH
Kako čuvati Klopidogrel ratiopharm GmbH
These may be due to rare decrease of some blood cells.
- vrućicu, znakove infekcije ili izrazitog umora; ti simptomi mogu biti posljedica rijetkog smanjenja broja nekih krvnih stanica..
In patients who were enrolled in the trial on the sole basis of a recent myocardial infarction, clopidogrel was numerically inferior, but not statistically different from ASA (RRR = -4.0%; CI: -22.5 to 11.7 [p=0.639]).
ASK (RRR = -4,0%; CI: -22,5 do 11,7 [p=0,639]).
Taste disturbances, ageusia
konstipacija, flatulencija
The number of patients experiencing the co-primary endpoint (CV death, MI, stroke or refractory ischaemia) was 1,035 (16.5%) in the clopidogrel-treated group and 1,187 (18.8%) in the placebo-treated group, a 14% relative risk reduction (95% CI of 6%-21%, p=0.0005) for the clopidogrel-treated group.
(18,8%) u skupini koja je primala placebo, što znači smanjenje relativnoga rizika od 14% (95% CI: 6% do 21%, p=0,0005) u skupini koja je primala klopidogrel.
Eye bleeding (conjunctival, ocular, retinal)
Krvarenje u oku (spojnica, unutrašnjost oka, mrežnica)
43 patients (13.4%) in the de-escalated DAPT group and in 85 patients (26.3%) in the unchanged DAPT group (p<0.01).
DAPT-om (4,0%) u odnosu na skupinu sa nepromijenjenim DAPT-om (p < 0,01).
Talk to your doctor or pharmacist before taking Clopidogrel ratiopharm GmbH: if you have a risk of bleeding such as a medical condition that puts you at risk of internal bleeding (such as a stomach ulcer) a blood disorder that makes you prone to internal bleeding (bleeding inside any tissues, organs or joints of your body) a recent serious injury a recent surgery (including dental) a planned surgery (including dental) in the next seven days if you have had a clot in an artery of your brain (ischaemic stroke) which occurred within the last seven days if you have kidney or liver disease if you have had an allergy or reaction to any medicine used to treat your disease
- medicinskih stanja kod kojih postoji opasnost od unutrašnjeg krvarenja (kao što je želučani čir) - poremećaja krvi zbog čega ste skloni unutrašnjim krvarenjima (krvarenje u tkivima, organima ili zglobovima) - nedavne teške ozljede
Film-coating:
PC:
1121 Vienna
1121 Beč
If you use more Beromun than you should
Ako primijenite više Beromuna nego što ste trebali
You must not use Beromun if you are pregnant.
Ne smijete primati Beromun ako ste trudni.
Night sweats
Noćno znojenje
What Beromun is and what it is used for
Što je Beromun i za što se koristi
The changes observed at the low dose of the 13-week studies can be classified as minimal and fully reversible.
Primijećene promjene pri niskoj dozi u 13-tjednim ispitivanjima mogu se klasificirati kao minimalne i potpuno reverzibilne.
The safety and efficacy of Beromun in children under 18 years have not been established.
Sigurnost i djelotvornost Beromuna u djece u dobi do 18 godina nisu ustanovljene.
Treatment with anti-TNFα antibodies is not recommended.
Liječenje anti-TNFα antitijelima se ne preporučuje.
Mechanism of action In vivo antitumour activity is probably based on direct and indirect effects:
Mehanizam djelovanja In vivo antitumorska aktivnost se vjerojatno temelji na direktnim i indirektnim učincima:
The temperature should then be increased to >39°C (but not exceeding 40°C) in two different sites of measurement in the tumour area.
Temperatura se zatim povećava na >39°C (ali ne preko 40°C) na dva različita mjesta mjerenja u području tumora.
Animal studies are insufficient with respect to effects on pregnancy, embryonal development and postnatal development (see section 5.3).
Ispitivanja na životinjama su nedostatna s obzirom na učinke na trudnoću, embrionalni razvoj i postnatalni razvoj (vidjeti dio 5.3).
Popliteal and brachial perfusions may not need more than 1 litre.
Za poplitealne i brahijalne perfuzije nije potrebno više od 1 litre.
In particular, you should tell your doctor if you are using medicines to lower blood pressure (to treat hypertension).
Osobito je važno obavijestiti liječnika ako uzimate lijekove za snižavanje krvnog tlaka (za liječenje hipertenzije).
For any information about this medicine, please contact the Marketing Authorisation Holder:
Za bilo kakve informacije u svezi s ovim lijekom, kontaktirajte Nositelja odobrenja za stavljanje lijeka u promet:
If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8 °C, unless reconstitution has taken place in controlled and validated aseptic conditions.
Ako se ne primijeni odmah, vrijeme i uvjeti čuvanja prije primjene su odgovornost korisnika te obično ne smiju biti dulji od 24 sata na 2 do 8°C, osim ako je rekonstitucija provedena u kontroliranim i validiranim aseptičkim uvjetima.
Beromun must not be administered systemically.
Beromun se ne smije primjenjivati sistemski.
However, the treatment is specifically a loco-regional treatment and is not expected to influence survival.
Međutim, liječenje je specifično lokoregionalno te se ne očekuje njegov utjecaj na preživljenje.
No evidence has been found of any mutagenic effect, neither in vivo nor in vitro.
Nisu pronađeni dokazi mutagenih učinaka in vivo ni in vitro.
Systemic adverse reactions include mild constitutional reactions and toxic effects on different organ systems.
Sistemske nuspojave uključuju blage konstitucijske reakcije i toksične učinke na različite organske sustave.
It is important that it does not reach other parts of your body, because this so-called systemic leakage could cause serious side effects on the main organs of the body.
Važno je da ne dođe u druge dijelove tijela, jer takozvano sistemsko propuštanje može izazvati ozbiljne nuspojave na glavnim organima u tijelu.
Date of first authorisation: 13 April 1999 Date of latest renewal: 25 March 2009
Datum posljednje obnove odobrenja: 25. ožujka 2009.
Pharmacotherapeutic group: Other immunostimulants, ATC code: L03AX11
Farmakoterapijska skupina: drugi imunostimulansi, ATK oznaka: L03AX11
2, Rue Albert 1er L-1117 Luxembourg Grand Duchy of Luxembourg Tel : +352 27403070
2, Rue Albert 1er L-1117 Luksemburg Veliko vojvodstvo Luksemburg Tel : +352 27403070
Very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000
(≥1/100 i <1/10), manje često (≥1/1000 i <1/100), rijetko (≥1/10 000 i <1/1000).
If there is significant systemic leakage of Beromun
U slučaju značajnog sistemskog propuštanja Beromuna
Nerve injury, peripheral neurotoxicity, altered state of consciouness, headache
Ozljeda živca, periferna neurotoksičnost, promijenjeno stanje svijesti, glavobolja
Reconstituted solution Chemical and physical in-use stability has been demonstrated for up to 48 hours at 25°C.
Rekonstituirana otopina Dokazana je kemijska i fizikalna stabilnost tijekom primjene do 48 sati na 25°C.
Hypercalcaemia > 12 mg/dl (2.99 mmol/l).
Hiperkalcemija > 12 mg/dl (2,99 mmol/l).
The terminal half-life at the maximum tolerated intravenous dose (150 µg/m2) was 15-30 min.
Poluvijek pri maksimalnoj intravenskoj podnošljivoj dozi (150 µg/m2) bio je 15-30 min.
If more than 10% of your Beromun dose reaches the main part of your body, your doctor will take similar measures as in the case of overdose.
Ako više od 10 % doze Beromuna dođe do nekog od glavnih organa u tijelu, liječnik će poduzeti mjere slične onima kod predoziranja.
For instructions on administration, see section 4.2.
Za upute o primjeni, vidjeti dio 4.2.
Severe pulmonary dysfunction.
Teška plućna disfunkcija.
For the prophylaxis of shock, patients should always be maximally hydrated prior to, during and after the perfusion procedure.
U svrhu sprječavanja šoka bolesnici moraju biti maksimalno hidrirani prije, tijekom i nakon postupka perfuzije.
Induction of general anaesthesia and subsequent mechanical ventilation should be applied according to standard methods.
Indukcija opće anestezije i daljnja mehanička ventilacija se primjenjuju prema standardnim metodama.
It belongs to a class of medicines known as immunostimulants, which help your body's immune system fight cancer cells.
Pripada skupini lijekova poznatih kao imunostimulansi koji pomažu Vašem imunološkom sustavu u borbi protiv stanica raka.
- The active substance is tasonermin.
- Djelatna tvar je tasonermin.
The perfusion should be terminated if the cumulative leakage into the systemic circulation is > 10%.
Perfuzija se prekida ako je kumulativno propuštanje u sistemsku cirkulaciju > 10 %.
2, Rue Albert 1er L-1117 Luxembourg Grand Duchy of Luxembourg
2, Rue Albert 1er L-1117 Luksemburg Veliko vojvodstvo Luksemburg
It is important to maintain a constant level of anaesthesia in order to prevent large fluctuations in systemic blood pressure, which can affect leakage between systemic circulation and perfusion circuit.
Važno je održavati stalnu razinu anestezije u cilju sprječavanja velikih fluktuacija u sistemskom krvnom tlaku koje bi mogle utjecati na propuštanje između sistemske cirkulacije i perfuzijskog kruga.
Melphalan dose should be calculated according to the litre-volume method of Wieberdink (Wieberdink J, Benckhuysen C, Braat RP, van Slooten EA, Olthius GAA.
Dozu melfalana potrebno je izračunati prema Wieberdinkovoj metodi litra-volumen (Wieberdink J, Benckhuysen C, Braat RP, van Slooten EA, Olthius GAA.
Simultaneous treatment with cardiotoxic substances (e.g. anthracyclines).
Istovremeno liječenje kardiotoksičnim tvarima (npr. antraciklini).
Fertility No data on the possible effect of this medicinal product on male and female fertility are available.
Nisu dostupni podaci o mogućem učinku ovog lijeka na mušku i žensku plodnost.
The circulatory changes included decreased blood pressure and, in some studies, increased heart rate and decreased contractility.
Cirkulacijske promjene uključivale su sniženi krvni tlak i, u nekim ispitivanjima, povećanu srčanu frekvenciju i smanjenu kontraktilnost.
Further, animals that reject experimental tumours following tasonermin treatment may develop specific immunity for this tumour cell type.
Nadalje, životinje kod kojih se eksperimentalni tumori ne prihvate nakon liječenja tasonerminom mogu razviti specifični imunitet za tu vrstu tumorskih stanica.
You must not breast-feed for at least seven days after treatment with Beromun.
Ne smijete dojiti najmanje sedam dana nakon liječenja Beromunom.
From a microbiological point of view, the reconstituted product should be used immediately.
S mikrobiološkog stajališta, rekonstituirani lijek se mora odmah primijeniti.
Therefore, whenever there is significant systemic leakage of tasonermin, serious undesirable effects are to be expected.
Stoga, kada god postoji značajno sistemsko propuštanje tasonermina, očekuju se ozbiljne nuspojave.
Some of the side effects can be serious, particularly if Beromun reaches other parts of your body (systemic leakage).
Neke od nuspojava mogu biti teške, osobito ako Beromun dosegne druge dijelove tijela (sistemsko propuštanje).
Contents of the pack and other information What Beromun contains
Sadržaj pakiranja i druge informacije Što Beromun sadrži
Melphalan:
Melfalan:
Clinical data however indicate that the overall incidence of adverse events is increased if patients are simultaneously exposed to tasonermin and interferon-gamma.
Međutim, klinički podaci pokazuju da je ukupna incidencija štetnih događaja povećana ako se bolesnici istovremeno izlažu tasonerminu i interferonu gama.